Skip to main content

Advertisement

Table 2 Gender-specific baseline characteristics of HF outpatients, by SUA quartiles

From: Gender differences in association between uric acid and all-cause mortality in patients with chronic heart failure

  All (n = 4684) Women (n = 1251) Men (n = 3443)
Women (n = 1251) Men (n = 3433) P-value SUA
Quartile 1–3
(n = 921)
SUA
Quartile 4
(n = 330)
P-value SUA
Quartile 1–3
(n = 2589)
SUA
Quartile 4
(n = 844)
P-value
Se-uric acid, μmol/L 435.2 ± 143.9 468.9 ± 127.1 < 0.001 367.4 ± 86.1 624.1 ± 96.6 < 0.001 413.3 ± 80.7 639.6 ± 84.3 < 0.001
Se-uric acid, mg/dL 7.32 ± 2.42 7.88 ± 2.14   6.18 ± 1.45 10.49 ± 1.62   6.95 ± 1.36 10.75 ± 1.42  
Age, years 72.1 ± 12.1 68.6 ± 12.1 < 0.001 70.7 ± 12.3 76.2 ± 10.4 < 0.001 68.1 ± 12.2 70.3 ± 11.6 < 0.001
Body mass index, kg/m2 25.6 ± 5.6 26.6 ± 4.9 < 0.001 25.4 ± 5.6 26.1 ± 5.4 0.054 26.4 ± 4.9 27.1 ± 5.2 0.001
Smoking, % 12.6 16.3 0.002 14.3 7.9 0.002 16.8 15.1 0.247
Medical history
 Diabetes mellitus, % 18.7 19.9 0.352 16.6 24.6 0.001 18.7 23.7 0.001
 Ischaemic heart disease, % 46.0 59.6 < 0.001 44.2 50.8 0.045 59.1 61.1 0.323
 Hypertension, % 37.1 30.2 < 0.001 33.5 47.1 < 0.001 28.4 35.6 < 0.001
 Claudication/stroke, % 13.6 15.8 0.071 13.4 14.1 0.777 14.9 18.4 0.016
 PCI/CABG, % 26.1 42.5 < 0.001 25.9 26.7 0.774 42.6 42.0 0.746
 Reduced renal function, % 51.3 40.1 < 0.001 39.7 83.6 < 0.001 31.3 67.3 < 0.001
Physical findings
 Heart rate, beats/min 73.5 ± 14.3 72.2 ± 15.2 0.008 73.1 ± 14.5 74.6 ± 13.7 0.105 71.9 ± 14.8 73.1 ± 16.1 0.044
 SBP, mmHg 128.2 ± 23.1 126.0 ± 22.0 0.004 128.9 ± 23.2 126.3 ± 22.8 0.079 127.2 ± 21.8 122.3 ± 22.4 < 0.001
 LVEF, % 35.8 ± 13.3 31.7 ± 10.8 < 0.001 35.3 ± 12.5 37.1 ± 15.3 0.092 32.0 ± 10.7 30.8 ± 10.9 0.007
LVEF groups    < 0.001    0.023    0.031
 LVEF< 40% 64.6 76.8   66.1 59.8   75.8 80.0  
 40%≤LVEF<50% 19.5 16.0   19.7 18.9   17.0 13.1  
 LVEF≥50% 15.9 7.2   14.1 21.2   7.2 6.9  
NYHA Class    0.001    < 0.001    < 0.001
 I + II, % 44.1 50.8   50.0 27.5   53.8 41.5  
 III + IV, % 55.9 49.2   50.0 72.5   46.2 58.4  
Medication
 RAS-blocking agent use, % 87.3 90.0 0.008 88.7 83.3 0.012 90.4 88.7 0.159
 ACEi dose/day, % of target dose 49.3 ± 40.0 53.2 ± 38.0 0.005 49.3 ± 36.9 49.4 ± 47.8 0.975 52.9 ± 37.7 54.2 ± 39.2 0.452
 ARB use, % 17.4 15.2 0.060 16.8 19.1 0.353 14.7 16.7 0.144
 β-blocker dose/day, mg 67.6 ± 62.2 72.6 ± 64.5 0.017 65.6 ± 60.0 73.1 ± 14.5 0.059 70.4 ± 63.7 79–4 ± 66.2 < 0.001
 Loop diuretics dose/day, mg 86.7 85.1 0.149 44.2 ± 45.6 90.4 ± 83.1 < 0.001 49.2 ± 51.5 86.4 ± 67.9 < 0.001
 Calcium channel blocker use, % 9.2 7.6 0.080 8.6 10.9 0.205 7.7 7.4 0.727
 Acetylsalicylic acid use, % 44.4 48.0 0.027 45.3 41.8 0.278 49.3 44.0 0.007
 Statin use, % 46.7 57.4 < 0.001 47.7 43.9 0.245 58.2 54.9 0.086
Laboratory values
 eGFR, ml/min/1.73 m2 60.3 ± 22.7 66.1 ± 22.3 < 0.001 66.0 ± 21.5 44.6 ± 18.1 < 0.001 70.2 ± 21.1 53.4 ± 21.1 < 0.001
 Haemoglobin, g/100 mL 13.31 ± 1.53 14.04 ± 1.74 < 0.001 13.32 ± 1.43 13.21 ± 1.77 0.202 14.09 ± 1.68 13.90 ± 1.90 0.010
 Se-potassium, mmol/L 4.32 ± 0.48 4.42 ± 0.46 < 0.001 4.32 ± 0.45 4.32 ± 0.53 0.950 4.41 ± 0.44 4.45 ± 0.51 0.055
 Se-sodium, mmol/L 139.4 ± 3.1 140.0 ± 3.1 < 0.001 139.6 ± 3.5 139.1 ± 3.5 0.047 140.0 ± 3.1 139.9 ± 3.1 0.331
 Se-cholesterol, mmol/L 5.08 ± 1.34 4.58 ± 1.22 < 0.001 5.06 ± 1.33 5.11 ± 1.38 0.588 4.59 ± 1.20 4.56 ± 1.28 0.561
  1. Values are expressed as mean ± SD or percent. ACEi dose/day, percent of daily enalapril equivalent target dose; ARB, angiotensin receptor blocker; β-blocker dose/day, daily metoprolol equivalent dose; eGFR, estimated glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PCI/CABG, percutaneous coronary intervention and/or coronary artery bypass graft; RAS-blocking agent, renin-angiotensin system blocking agent; SBP, systolic blood pressure; SUA serum uric acid